Immunopathogenic Treatment Options for Psoriasis Patients Under a Restrictive Reimbursement Environment

Ilona Hartmane; Iveta Ivdra; Ingmārs Mikažāns; Vanda Bondare-Ansberga

doi:10.2478/prolas-2021-0025

.blurhash-client-img { display: none !important; }

Immunopathogenic Treatment Options for Psoriasis Patients Under a Restrictive Reimbursement Environment

Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.

Volume 75 (2021): Issue 3 (June 2021)

By: Ilona Hartmane, Iveta Ivdra, Ingmārs Mikažāns and Vanda Bondare-Ansberga

Open Access

|Jul 2021

Abstract

This article is aimed to provide an overview of psoriasis clinical aspects, available treatment options for moderate-to-severe psoriasis in Baltics and summarises recommendations of authors for use of different biologicals in psoriasis patients under a limited reimbursement environment.

References

Benezeder, T., Wolf, P. (2019). Resolution of plaque-type psoriasis: What is left behind (and reinitiates the disease). Springer Semin. Immunopathol, 32 (6), 1–12.10.1007/s00281-019-00766-z688141431673756
Search in Google Scholar Back to article
Boehncke, W. H., Boehncke, S. (2014). More than skin-deep: The many dimensions of the psoriatic disease. Swiss Med. Wkly., 144 (171), 68–75.10.4414/smw.2014.1396824764145
Search in Google Scholar Back to article
Boniface, K., Jacquemin, C., Darrigade, A. S., Dessarthe, B., Martins C., Boukhedouni, N. (2018). Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3. J. Invest. Dermatol., 138 (2), 355–364.10.1016/j.jid.2017.08.03828927891
Search in Google Scholar Back to article
Cather, J. C., Crowley, J. J. (2014). Use of biologic agents in combination with other therapies for the treatment of psoriasis. Amer. J. Clin. Dermatol., 15 (6), 467–478.10.1007/s40257-014-0097-1423982525373522
Search in Google Scholar Back to article
Chiricozzi, A., Romanelli,. P., Volpe, E., Borsellino, G., Romanelli, M. (2018). Scanning the immunopathogenesis of psoriasis. Int. J. Mol. Sci., 19 (1), 179–18510.3390/ijms19010179579612829316717
Search in Google Scholar Back to article
Christophers, E. (2001) Psoriasis — epidemiology and clinical spectrum. Clin. Exp. Dermatol., 26 (4), 314–320.10.1046/j.1365-2230.2001.00832.x11422182
Search in Google Scholar Back to article
Christophers, E., van de Kerkhof, P. C. (2019). Severity, heterogeneity and systemic inflammation in psoriasis. J. Eur. Acad. Dermatol. Venereol., 33 (4), 643–647.10.1111/jdv.1533930924245
Search in Google Scholar Back to article
Cosentyx 150 mg powder for solution for injection. SmPC. https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf (accessed 15 March 2020).
Search in Google Scholar Back to article
Danese, S., Vermeire, S., D’Haens, G., Panés J., Dignass, A., Magro F. (2020). DOP13 Clinical and endoscopic response to ustekinumab in Crohn’s disease: Week 16 interim analysis of the STARDUST trial. J. Crohns Colitis, 14 (1), 49–52.10.1093/ecco-jcc/jjz203.052
Search in Google Scholar Back to article
Dubertret, L., Mrowietz, U., Rank., A, Van De Kerkhof, P. C., Chimenti, S., Lotti, T. (2006). EUROPSO patient survey. European patient perspectives on the impact of psoriasis: The EUROPSO patient membership survey. Brit. J. Dermatol., 155 (4), 729–736.
Search in Google Scholar Back to article
Eder, L., Haddad, A., Rosen C. F., Lee K. A., Chandran V., Cook, R. (2016). The incidence and risk factors for psoriatic arthritis in patients with psoriasis: A prospective cohort study. Arthritis Rheum., 68 (4), 915–923.10.1002/art.3949426555117
Search in Google Scholar Back to article
Enbrel 25 mg solution for injection in pre-filled syringe Enbrel 50 mg solution for injection in pre-filled syringe. SmPC. https://www.ema.europa.eu/en/documents/product-information/enbrel-epar-product-information_en.pdf on 10/03/2020 (accessed 01.03.2020).
Search in Google Scholar Back to article
From evolution to revolution: IL-23 in the treatment of psoriasis patients. EMJ Dermatol., 6, 71–78. https://www.emjreviews.com/dermatology/symposium/from-evolution-to-revolution-il-23-in-the-treatment-of-psoriasis-patients (accessed 01.03.2020).
Search in Google Scholar Back to article
Gaies, E., Jebabli, N., Trabelsi, S., Salouage, I., Charfi, R., Lakhal, M. (2012). Methotrexate side effects: Review article. J. Drug Metab. Toxicol., 3 (4), 1–5.10.4172/2157-7609.1000125
Search in Google Scholar Back to article
Gisondi, P., Del Giglio, M., Girolomoni, G. (2017). Treatment approaches to moderate to severe psoriasis. Int. J. Mol., 18 (11), 2427–2429.10.3390/ijms18112427
Search in Google Scholar Back to article
Global Psoriasis Atlas. https://globalpsoriasisatlas.org/statistics (accessed 20.04.2020).
Search in Google Scholar Back to article
Gooderham, M. J., Papp, K. A., Lynd, C.W. (2018). Shifting the focus–the primary role of IL-23 in psoriasis and other inflammatory disorders. J. Eur. Acad. Dermatol. Venereol., 32 (7), 1111–1119.10.1111/jdv.14868
Search in Google Scholar Back to article
Griffiths, C. E., Barker, J. N. (2007). Pathogenesis and clinical features of psoriasis. The Lancet, 370, 263–271.10.1016/S0140-6736(07)61128-3
Search in Google Scholar Back to article
Hao, J. Q. (2014). Targeting interleukin-22 in psoriasis. Inflammation, 37 (1), 94–99.10.1007/s10753-013-9715-y23978911
Search in Google Scholar Back to article
Hartmane, I., Mikažāns, I., Ivdra,. I, Dērveniece, A., Ančupāne, I. (2016). Experience of phototherapy in dermatological praxis in complex therapy of psoriasis patients. Proc. Latv. Acad. Sci. Section B, 70 (1), 7–12.10.1515/prolas-2016-0002
Search in Google Scholar Back to article
Humira 40 mg solution for injection in pre-filled syringe Humira 40 mg solution for injection in pre-filled pen. SmPC. Last revised 08/09/2008. https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf (accessed 15.03.2020).
Search in Google Scholar Back to article
Ilumetri 100 mg solution for injection in pre-filled syringe. SmPC. Last revised 17/09/2018. https://www.ema.europa.eu/en/documents/product-information/ilumetri-epar-product-information_en.pdf on 10/03/2020 (accessed 15.03.2020).
Search in Google Scholar Back to article
Jain, S., Kaur, I. R., Das, S., Bhattacharya, S. N. Singh, A. (2009) T helper 1 to T helper 2 shift in cytokine expression: An autoregulatory process in superantigen-associated psoriasis progression? J. Med. Microbiol., 58 (2), 180–184.10.1099/jmm.0.003939-019141734
Search in Google Scholar Back to article
Kerdel, F., Zaiac, M. (2015). An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol. Ther., 28 (6), 390–403.10.1111/dth.12267504207326258910
Search in Google Scholar Back to article
Kyntheum 210 mg solution for injection in pre-filled syringe. SmPC. Last revised 17/07/2017. https://www.ema.europa.eu/en/documents/product-information/kyntheum-epar-product-information_en.pdf (accessed 15.03. 2020).
Search in Google Scholar Back to article
Li, K., Joshua, F. R., Marano, C., Zhang, H., Yang, F., Feagan, B. G. (2019). Effects of ustekinumab induction therapy on endoscopic and histologic healing in the UNIFI phase 3 study in Ulcerative Colitis. Z. Gastroenterol., 57 (5), 169–187.10.1055/s-0039-1691867
Search in Google Scholar Back to article
Mahil, S. K., Capon, F., Barker J. N. (2016). Update on psoriasis immuno-pathogenesis and targeted immunotherapy. Springer Semin. Immunopathol., 38 (1), 11–27.
Search in Google Scholar Back to article
Malik, B. T., Byrne, K. T., Vella, J. L., Zhang, P., Shabaneh, T. B., Steinberg, S. M. (2017). Resident memory T cells in skin mediate durable immunity to melanoma. Sci. Immunol., 2 (10), 35–47.10.1126/sciimmunol.aam6346552533528738020
Search in Google Scholar Back to article
Marti, D. A.,Towne, J. E., Kricorian, G., Klekotka, P., Gudjonsson, J. E., Krueger, J. G. (2013). The emerging role of IL-17 in the pathogenesis of psoriasis: Preclinical and clinical findings. J. Invest Dermatol., 133 (1), 17–26.10.1038/jid.2012.194356899722673731
Search in Google Scholar Back to article
Matos, T. R., O’Malley, J. T., Lowry, E. L., Hamm, D., Kirsch I. R. (2017). Clinically resolved psoriatic lesions contain psoriasis-specific IL-17–producing αā T cell clones. J. Clin. Invest., 127 (11), 4031–4041.10.1172/JCI93396566336628945199
Search in Google Scholar Back to article
Mattozzi, C., Salvi M., D’epiro, S., Giancristoforo, S., Macaluso, L., Luci, C. (2013). Importance of regulatory T cells in the pathogenesis of psoriasis. Dermatology, 227 (2), 134–145.10.1159/00035339824051528
Search in Google Scholar Back to article
Medicines to be reimbursed. Nacionālais Veselības Dienests [National Health Service]. http://www.vmnvd.gov.lv/en/cross-border-healthcare-contact-point/health-care-in-latvia/medicines-to-be-reimbursed on 06/04/2020 (accessed 15.04. 2020).
Search in Google Scholar Back to article
Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. M., Gordon, K. B. (2011). Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions. J. Amer. Acad. Dermatol., 65 (1), 137–174.10.1016/j.jaad.2010.11.05521306785
Search in Google Scholar Back to article
Ministry of Health of the Republic of Lithuania. http://sam.lrv.lt/en/ (accessed 15.04.2020).
Search in Google Scholar Back to article
Möller, A. H, Erntoft, S., Vinding, G. R., Jemec G. B. (2015). A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values. Patient Relat. Outcome Meas., 6, 167–177.
Search in Google Scholar Back to article
Monteleone, G., Pallone F., MacDonald, T. T., Chimenti, S., Costanz, A. (2011). Psoriasis: From pathogenesis to novel therapeutic approaches. Clin. Sci., 120 (1), 8–12.10.1042/CS2010016320846119
Search in Google Scholar Back to article
Mrowietz, U., De Jong, E. M., Kragballe, K., Langley, R., Nast, A., Puig, L. (2014). A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J. Eur. Acad. Dermatol. Venereol., 28 (4), 438–453.10.1111/jdv.1211823437792
Search in Google Scholar Back to article
Mrowietz, U., Kragballe, K., Reich, K., Spul, P., Griffiths. C. E., Nast, A. (2011). Definition of treatment goals for moderate to severe psoriasis:A European consensus. Arch. Dermatol. Res., 303 (1), 1–10.
Search in Google Scholar Back to article
Nast, A., Boehncke, W. H., Mrowietz, U., Ockenfels, H. M., Philipp, S., Reich, K. (2012). S3–Guidelines on the treatment of psoriasis vulgaris (English version). Update. J. Dtsch. Dermatol. Ges., 10, 1–95.10.1111/j.1610-0387.2012.07919.x22386073
Search in Google Scholar Back to article
Order for the approval of the procedure for the treatment of psoriasis with medicinal products the purchase of which is covered by the compulsory health insurance fund’s budget. Ministry of Health of Republic of Lithuania. https://www.e-tar.lt/portal/en/legalAct/c51f3b408d8311e7a3c4a5eb10f04386/nHZdKhSspS on 06/04/2020 (accessed 15.04.2020) (in Lithuanian).
Search in Google Scholar Back to article
Owczarczyk-Saczonek, A., Czerwińska, J., Placek, W. (2018). The role of regulatory T cells and anti-inflammatory cytokines in psoriasis. Acta Dermatovenerol. Alp. Pannonica Adriat., 27 (1), 17–23.10.15570/actaapa.2018.4
Search in Google Scholar Back to article
Parisi, R., Symmons, D. P, Griffiths, C. E, Ashcrof, D. M.(2013). Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J. Investig. Dermatol.., 133 (2), 377–385.10.1038/jid.2012.33923014338
Search in Google Scholar Back to article
Qu, N., Xu, M., Mizoguchi, I., Furusawa, J. I., Kaneko, K., Watanabe, K. (2013). Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clin. Dev. Immunol., 34 (16), 231–235.10.1155/2013/968549372850723956763
Search in Google Scholar Back to article
Rahman, P., Elder, J. T. (2005). Genetic epidemiology of psoriasis and psoriatic arthritis. Ann. Rheum. Dis., 64 (2), 37–49.10.1136/ard.2004.030775176686815708933
Search in Google Scholar Back to article
Rahman, P., Siannis, F., Butt, C., Farewell, V., Peddle, L., Pellett, F (2006). TNFα polymorphisms and risk of psoriatic arthritis. Ann. Rheum. Dis., 65 (7), 919–923.
Search in Google Scholar Back to article
Reich, K., Armstrong, A. W., Langley, R. G., Flavin, S., Randazzo, B., Li, S (2019). Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): Results from a phase 3, randomised controlled trial. The Lancet, 394 (1 0201), 831–839.10.1016/S0140-6736(19)31773-8
Search in Google Scholar Back to article
Reich, K. (2012). The concept of psoriasis as a systemic inflammation: Implications for disease management. J. Eur. Acad. Dermatol. Venereol., 26, 3–11.10.1111/j.1468-3083.2011.04410.x22356630
Search in Google Scholar Back to article
Reich, K., Burden, A. D., Eaton, J. N., Hawkins, N. S. (2012). Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials. Brit. J. Dermatol., 166 (1), 179–188.10.1111/j.1365-2133.2011.10583.x21910698
Search in Google Scholar Back to article
Reich, K., Nestle, F. O., Papp, K., Ortonne, J. P., Evans, R, Guzzo, C., Li, S., Dooley, L. T., Griffiths, C. E., (2005). EXPRESS Study Investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. The Lancet, 366 (9494), 1367–1374.
Search in Google Scholar Back to article
Reimbursemen drug list. Nacionālais Veselības Dienests [National Health Service]. http://www.vmnvd.gov.lv/lv/kompensejamie-medikamenti/kompensejamo-zalu-saraksts from 06/04/2020 (accessed 15.04. 2020).10.36268/JTER/15202
Search in Google Scholar Back to article
Remsima 100 mg powder for concentrate for solution for infusion. SmPC. Last revised 21/06/2018. https://www.ema.europa.eu/en/documents/product-information/remsima-epar-product-information_en.pdf (accessed 15.04. 2020).
Search in Google Scholar Back to article
Rendon, A, Schäkel, K. (2019). Psoriasis pathogenesis and treatment. Int. J. Mol. Sci., 20 (6), 1475.10.3390/ijms20061475647162830909615
Search in Google Scholar Back to article
Signorovitch, J. E., Betts, K.A., Yan, Y. S., LeReun, C., Sundaram, M., Wu, E. Q., Mulani, P. (2015). Comparative efficacy of biological treatments for moderate-to-severe psoriasis: A network meta-analysis adjusting for cross-trial differences in reference arm response. Brit. J. Dermatol., 172 (2), 504–512.10.1111/bjd.1343725288183
Search in Google Scholar Back to article
Skyrizi 75 mg solution for injection in pre-filled syringe. SmPC. Last revised 26/04/2019. https://www.ema.europa.eu/en/documents/product-information/skyrizi-epar-product-information_en.pdf (accessed 15.04.2020).
Search in Google Scholar Back to article
STELARA 45 mg solution for injection STELARA 90 mg solution for injection STELARA 45 mg solution for injection in pre-filled syringe STELARA 90 mg solution for injection in pre-filled syringe. SmPC. Last revised 19/09/2013. https://www.ema.europa.eu/en/documents/product-information/stelara-epar-product-information_en.pdf (accessed 15.04.2020).
Search in Google Scholar Back to article
Takeshita, J., Grewal, S., Langan, S. M., Mehta, N. N., Ogdie A., Van Voorhees A. S. (2017). Psoriasis and comorbid diseases: Epidemiology. J. Amer. Acad. Dermatol.. 76 (3), 377–390.10.1016/j.jaad.2016.07.064573165028212759
Search in Google Scholar Back to article
Taltz 80 mg solution for injection in pre-filled syringe. SmPC. Last revised 25/04/2016. https://www.ema.europa.eu/en/documents/product-information/taltz-epar-product-information_en.pdf (accessed 15.04. 2020).
Search in Google Scholar Back to article
Tervishoiuteenuste loetelu. https://www.haigekassa.ee/partnerile/raviasutusele/tervishoiuteenuste-loetelu on 06/04/2020 (accessed 15.04.2020).10.1055/s-0040-1721630
Search in Google Scholar Back to article
Tremfya 100 mg solution for injection in pre-filled syringe. Tremfya 100 mg solution for injection in pre-filled pen. SmPC. Last revised 10/11/2017. https://www.ema.europa.eu/en/documents/product-information/tremfya-epar-product-information_en.pdf (accessed 15.04. 2020).
Search in Google Scholar Back to article
Use of public budget resources to pay national reimburses [Valsts budžeta līdzekļu izlietojums valsts kompensējamo zāļu apmaksā]. Nacionālais Veselības Dienests [National Health Service]. http://vmnvd.gov.lv/lv/ligumpartneriem/operativa-budzeta-informacija/valsts-budzeta-lidzeklu-izlietojums-valsts-kompensejamo-zalu-apmaksa on 07/04/2020 (accessed 15.04.2020).
Search in Google Scholar Back to article
Vide, J., Magina S, (2017). Moderate to severe psoriasis treatment challenges through the era of biological drugs. An. Bras. Dermatol., 92 (5), 668–674.10.1590/abd1806-4841.20175603567470029166504
Search in Google Scholar Back to article
Wada, Y., Cardinale, I., Khatcherian, A., Chu, J., Kantor, A. B., Gottlieb, A.B. (2012). Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis. PloS One, 7 (4), 1371–1380.10.1371/journal.pone.0035069332087322493730
Search in Google Scholar Back to article
Watanabe, R. (2019). Protective and pathogenic roles of resident memory T cells in human skin disorders. J. Dermatol. Sci., 31 (5), 151–157.10.1016/j.jdermsci.2019.06.00131272851
Search in Google Scholar Back to article
Yeung, H., Takeshita, J., Mehta, N. N., Kimmel, S. E., Ogdie, A., Margolis, D. J., Shin, D. B., Attor, R., Troxel, A. B., Gelfand, J. M. (2013). Psoriasis severity and the prevalence of major medical comorbidity: A population-based study. JAMA Dermatol., 149 (10), 1173–1179.10.1001/jamadermatol.2013.5015380048723925466
Search in Google Scholar Back to article